Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) is a clinical-stage gene editing company focused on developing in vivo therapies for genetic and infectious diseases using its proprietary ARCUS platform. The filing covers the fiscal year ended December 31, 2024. The company operates as a single segment and is classified as a smaller reporting company and non-accelerated filer.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $68.7 million | $48.7 million |
| Net Income (Loss) | $7.2 million | $(61.3) million |
| Operating Loss | $(26.2) million | $(43.7) million |
| Research & Development Expenses | $59.6 million | $53.4 million |
| General & Administrative Expenses | $35.3 million | $39.1 million |
| Cash, Cash Equivalents, and Restricted Cash | $108.5 million | $116.7 million |
| Accumulated Deficit | $(482.5) million | $(489.6) million |
| Debt Outstanding | $22.5 million (Term Loan) | $22.4 million (Revolving Line) |
Note: The 2024 net income includes a non-cash gain of $29.6 million related to the change in fair value of warrant liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by $20.0 million (41%) primarily due to the recognition of remaining deferred revenue from the terminated Prevail Therapeutics agreement ($26.7 million increase) and new revenue from the TG Therapeutics and Caribou Biosciences agreements ($9.5 million increase). This was partially offset by a $16.3 million decrease in revenue from the Novartis agreement.
- Profitability: The company reported a net income of $7.2 million in 2024 compared to a net loss of $61.3 million in 2023. This turnaround was driven by a $29.6 million non-cash gain on the change in fair value of warrant liabilities and a reduction in operating losses.
- Debt Restructuring: In July 2024, the company replaced its revolving line of credit with a $22.5 million term loan from Banc of California, maturing in June 2027. The company is required to maintain a cash security account equal to the loan principal.
- Discontinued Operations: The company sold its CAR T cell therapy platform to Imugene in 2023. Consequently, 2023 results included a loss from discontinued operations of $18.8 million, whereas 2024 had no discontinued operations.
Guidance, Outlook, and Risks
- Cash Runway: Management believes existing cash, expected operational receipts, and the availability of its At-The-Market (ATM) facility are sufficient to fund operations into the second half of 2026. This runway is expected to support first-in-human Phase 1 clinical data for two wholly-owned programs.
- Clinical Progress:
- PBGENE-HBV: The ELIMINATE-B trial is actively enrolling. The first patient was dosed in December 2024, and the low-dose cohort (N=3) completed the initial safety evaluation with no Grade 2+ treatment-related adverse events. Substantial reduction in HBsAg was observed in two of three participants.
- PBGENE-3243: Preclinical data supports the program for mitochondrial disease; an IND/CTA submission is anticipated in 2025.
- Partnered Programs: iECURE reported a complete clinical response in the first infant dosed with ECUR-506 for OTC deficiency in January 2025.
- Risks and Contingencies:
- Capital Needs: The company expects to continue incurring significant operating losses. It may need to raise additional capital, which could be dilutive or require relinquishing rights to technologies.
- Regulatory Uncertainty: As a clinical-stage company, there is no assurance that product candidates will obtain regulatory approval or achieve commercial success.
- Collaboration Dependence: Revenue is heavily dependent on collaboration agreements (e.g., Novartis, TG Therapeutics). The termination of the Prevail agreement in 2024 resulted in the return of three programs to the company.
- Warrant Liability: The company has a warrant liability of $2.8 million as of December 31, 2024, which is subject to remeasurement and impacts net income.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of revenue streams given the termination of the Prevail agreement and the reliance on milestone payments and deferred revenue recognition from partners like Novartis and TG Therapeutics.
- Cash Burn vs. Runway: Confirm the accuracy of the "second half of 2026" cash runway estimate, considering the $22.5 million restricted cash requirement under the new term loan and the potential need for additional financing.
- Non-Cash Gains: Note that the 2024 net income is significantly influenced by a $29.6 million non-cash gain on warrant liabilities; operating cash flow remains negative at $(58.4) million.
- Clinical Milestones: Monitor the safety and efficacy data from the PBGENE-HBV ELIMINATE-B trial and the iECURE OTC-HOPE study, as these are critical for future valuation and partnership leverage.
- Debt Covenants: Review the covenants of the 2024 Term Loan, specifically the requirement to maintain $22.5 million in a restricted cash account, which limits liquidity flexibility.